R&D Successes Celebrated At 2018 CARE Awards
Executive Summary
Informa Pharma Intelligence pays tribute to the people driving the advances in drug development and their commitments to advancing human health with the third annual CARE Awards.
You may also be interested in...
Putting Innovation In The Spotlight
The Clinical and Research Excellence (CARE) Awards are Informa Pharma Intelligence's way of honoring the R&D accomplishments across the biopharmaceutical industry. Nominations are free and open through Jan. 19.
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Gilead's newly acquired CAR-T therapy Yescarta, developed by Kite Pharma, won FDA approval for certain B cell lymphomas on Oct. 18 and the company set its price $102,000 below Novartis's competing therapy Kymriah, which was approved in a small pediatric leukemia indication.
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.